Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Finn

Showing results (381-390 of 527) with videos related to

Pageof 53
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast CancerRichard S Finn, Yuan Liu, Zhou Zhu, et al.
Cancer Cell|March 15, 2011
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screeningEric T Sawey, Maia Chanrion, Chunlin Cai, et al.
Journal of the American College of Surgeons|April 6, 2011
Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinomaJohnny C Hong, Henrik Petrowsky, Fady M Kaldas, et al.
The Journal of Allergy and Clinical Immunology|March 22, 2017
Absence of functional fetal regulatory T cells in humans causes in utero organ-specific autoimmunityEric J Allenspach, Laura S Finn, Mara H Rendi, et al.
The Journal of Allergy and Clinical Immunology. Global|September 10, 2024
Granulomatous hyperinflammatory state induced by dupilumab treatment for eosinophilic esophagitisKanak V Kennedy, Anna Costello, Melissa A Lerman, et al.
JAMA Oncology|October 5, 2023
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical TrialShukui Qin, Masatoshi Kudo, Tim Meyer, et al.
Biochemical Pharmacology|September 14, 1999
Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell linesJ T Lim, G A Piazza, E K Han, et al.
Scientific Reports|November 24, 2019
Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistanceS Inder, M Bates, N Ni Labhrai, et al.
Future Oncology (London, England)|November 2, 2023
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial resultsHope S Rugo, Seock-Ah Im, Anil A Joy, et al.
The Oncologist|January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-UpRichard S Finn, Hope S Rugo, Karen A Gelmon, et al.
Pageof 53

Showing results (381-390 of 527) with videos related to

Sort By:
Pageof 53
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast CancerRichard S Finn, Yuan Liu, Zhou Zhu, et al.
Cancer Cell|March 15, 2011
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screeningEric T Sawey, Maia Chanrion, Chunlin Cai, et al.
Journal of the American College of Surgeons|April 6, 2011
Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinomaJohnny C Hong, Henrik Petrowsky, Fady M Kaldas, et al.
The Journal of Allergy and Clinical Immunology|March 22, 2017
Absence of functional fetal regulatory T cells in humans causes in utero organ-specific autoimmunityEric J Allenspach, Laura S Finn, Mara H Rendi, et al.
The Journal of Allergy and Clinical Immunology. Global|September 10, 2024
Granulomatous hyperinflammatory state induced by dupilumab treatment for eosinophilic esophagitisKanak V Kennedy, Anna Costello, Melissa A Lerman, et al.
JAMA Oncology|October 5, 2023
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical TrialShukui Qin, Masatoshi Kudo, Tim Meyer, et al.
Biochemical Pharmacology|September 14, 1999
Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell linesJ T Lim, G A Piazza, E K Han, et al.
Scientific Reports|November 24, 2019
Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistanceS Inder, M Bates, N Ni Labhrai, et al.
Future Oncology (London, England)|November 2, 2023
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial resultsHope S Rugo, Seock-Ah Im, Anil A Joy, et al.
The Oncologist|January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-UpRichard S Finn, Hope S Rugo, Karen A Gelmon, et al.
Pageof 53